Genomic alterations affecting components of the mechanistic target of rapamycin (mTOR) pathway are found rather frequently in cancers, suggesting that aberrant pathway activity is implicated in oncogenesis of different tumor types. mTOR functions as the core catalytic kinase of two distinct complexes, mTOR complex 1 (mTORC1) and 2 (mTORC2), which control numerous vital cellular processes. There is growing evidence indicating that Rictor, an essential subunit of the mTORC2 complex, is inappropriately overexpressed across numerous cancer types and this is associated with poor survival. To date, the candidate mechanisms responsible for aberrant Rictor expression described in cancer are two: (i) gene amplification and (ii) epigenetic regulation, mainly by microRNAs. Moreover, different mTOR-independent Rictor-containing complexes with oncogenic role have been documented, revealing alternative routes of Rictor-driven tumorigenesis, but simultaneously, paving the way for identifying novel biomarkers and therapeutic targets. Here, we review the main preclinical and clinical data regarding the role of Rictor in carcinogenesis and metastatic behavior as well as the potentiality of its alteration as a target.
Introduction
There is increasing evidence supporting that different pathological conditions, including neurological and cardiovascular diseases, metabolic syndromes and cancer are linked to an aberrant activity of the mechanistic target of rapamycin (mTOR) pathway (1) . mTOR is a well-conserved 289 kDa serine/threonine kinase that exists at least in two structurally and functionally distinct multiprotein complexes in mammalian cells, mTOR complex 1 and 2 (mTORC1 and mTORC2) (2) . Through these complexes, the mTOR pathway integrates incoming stimuli (growth factors, nutrients, oxygen) and translates them into essential cellular functions, such as survival, growth and proliferation. The mTOR kinase is strongly interconnected with the PTEN/PI3K/Akt axis, as well as with many other crucial pathways, eventually establishing an intricate signaling network. Different genetic alterations including somatic mutations and copy number variations usually affect the elements of these cascades, further influencing mTOR activity under pathological conditions. Although a wide range of clinical trials have been designed, testing different PI3K/mTOR/Akt inhibitors in cancers, to date only limited evidence of efficacy is available (2) . The successful introduction of targeted therapy against cancer strengthened the biological and clinical rationale for exploring and identifying a reliable target that might drive the efficacy of a candidate drug. In this review, we discuss the preclinical and clinical data regarding Rictor, an indispensable subunit of mTORC2 complex, supporting its key role in carcinogenesis and metastatic behavior.
mTORC1 and mTORC2 complexes
Both complexes share the same central catalytic subcomponent mTOR, the scaffolding protein mammalian lethal with SEC13 8 (mLST8) and the negative regulatory subunit DEP domaincontaining mTOR-interacting protein (Deptor) (3, 4) . mTORC1 and mTORC2 are defined by the presence of the accessory subunits regulatory associated protein of mTOR (Raptor) and rapamycin-insensitive companion of mTOR (Rictor), respectively. Furthermore, several components and interacting proteins participate in the assembly, control and activity of the two complexes (Table 1) (5) (6) (7) (8) . mTORC1 senses and responds to a wide array of stimuli, including growth factors, nutrients, and environmental stresses. Growth factors and high nutrient availability generally stimulate mTORC1 to promote cell proliferation through favoring anabolic processes and downregulating autophagy. Growth factors are the only well-defined stimulus for mTORC2, which promotes cell survival, proliferation, and migration along with actin cytoskeleton reorganization through phosphorylation and activation of downstream kinases including Akt, protein kinase C and serum/glucocorticoid-induced kinase 1. Although mTORC1 signaling is acutely sensitive to rapamycin, mTORC2 is considered insensitive and only prolonged treatment impairs its function in certain cell lines (9) . Τhe mTORC2 complex is an essential downstream effector of the PI3K signaling pathway and carries out the critical step of Akt activation by phosphorylating the residue S473 on its C-terminal hydrophobic motif. Upon activation, Akt plays a strong oncogenic role by either inducing or inhibiting downstream transcription factors (10) . An overview of the mTORC1/2-Rictor signaling network is presented in Figure 1 .
Rictor and Akt S473 phosphorylation: the key oncogenic event
Rictor protein consists of 1.708 amino acids and was initially identified in 2004 as a novel component of the mTORC2 complex (11) .
Rictor harbors approximately 37 phosphorylation sites, mainly serine or threonine residues lying in the C-terminal region (12) . Of these phosphorylation sites, Thr1135 was demonstrated to be a growth factor-stimulated and rapamycin-sensitive site as it is targeted directly by ribosomal protein S6 kinase 1, an mTORC1 downstream effector (12) . Although there is concordance among studies that this site is not mandatory for mTORC2 complex assembly, it still remains controversial whether the Thr1135 phosphorylation exerts a regulatory role or is dispensable for modulation of mTORC2 kinase activity (12, 13) . Nevertheless, it is widely supported that S6 kinase 1-mediated phosphorylation of Rictor-Thr1135 could define a model of a regulatory link between the two mTOR branches. Since the first relevant studies, Rictor was demonstrated to have a crucial role in the phosphorylation events of Akt kinase. Two amino acid residues, T308 and S473, have a critical role in Akt activation, triggering downstream oncogenic mechanisms (10) . Silencing of RICTOR in different human cancer cell lines diminished the phosphorylation of the Akt at S473, which is reported to increase kinase activity 4-5 times more than the phosphorylation at T308 alone (14) . In addition, data generated from in vitro experiments in adipocytes concluded that mTORC2-Rictor containing complex mediates the phosphorylation of Akt on S473 (15) . Although mTOR protein assembles into two complexes with distinct components and downstream effectors, they appeared to be reciprocally influenced by feedback loop mechanisms (16) . Treatment of tumor cell lines and rat models with mTORC1 inhibitors induced Akt S473 phosphorylation in a Rictor-dependent manner, probably related to S6 kinase 1 inactivation. Genetic silencing of RICTOR or use of the dual PI3K/mTOR inhibitor NVP-BEZ235 attenuated this effect (17, 18) .
Impact of Rictor in cancer
As mTOR, Rictor is essential for the development of mouse embryo. However, RICTOR null mice die later during development (midgestation) compared with mTOR null mice (around time of implantation) (19) . In addition RICTOR-deficient mouse embryonic fibroblasts completely lacked phosphorylation of Akt on S473 indicating that mTORC2 is the primary kinase for this AKT residue (19) . Moreover, Rictor is involved in the proper function and morphology of the neurons in murine brain (20, 21) . Rictor has been implicated in several diseases including polycystic kidney and benign tumors (22, 23) . However, the major amount of evidence originated from malignancies ( Table 2) .
Lung cancer
The first evidence for the implication of Rictor in lung cancer was the identification of RICTOR gene amplification as the only genomic aberration in the lung adenocarcinoma of a never smoker 18 years old male (24) . Treatment of the patient with dual mTORC1/2 inhibitors (CC-223 and MLN0128) provided disease stabilization for more than 18 months (24) . This clinical benefit prompted in vitro and in vivo experiments that demonstrated the sensitivity of RICTOR-amplified non-small-cell lung cancer cell lines to both dual mTORC1/2 inhibitors and RICTOR genetic silencing, suggesting the potential role of Rictor as a druggable target (24) . The evaluation of The Cancer Genome Atlas database showed that RICTOR amplification is present in approximately 10% of lung adenocarcinoma and 16% of lung squamous cell carcinomas. The analysis of an independent lung cancer cohort was in agreement with The Cancer Genome Atlas findings (24, 25) . In a recent study of lung neuroendocrine tumors comprising different histological subtypes, RICTOR copy number gains were found in 23.6% of cases (26) . Other cohorts reported a prevalence of RICTOR alterations in small-cell lung cancer (SCLC) ranging from 6 to 14%. In these reports, RICTOR amplification was almost invariably the only actionable alteration and negatively affected patients' overall survival (OS) (27) (28) (29) . RICTOR-amplified SCLC cells showed enhanced migratory activity and the use of mTOR inhibitors restrained this phenotype and strongly inhibited their growth (29) . In a large series of non-small-cell lung cancer patients treated with platinum-based chemotherapy, the RICTOR genetic variant rs6878291 (A>G), was associated with lower rate of clinical benefit and shorter progression-free survival (30) . An assessment of Rictor protein expression, but not its genetic status, was performed in primary and brain metastatic lung adenocarcinoma. An increased Rictor and Rictor/mTOR expression was reported in brain metastases compared with the primary lung adenocarcinoma. Moreover, a trend toward significance has been reported between Rictor expression and higher stage of primary adenocarcinoma. Interestingly, Rictor expression was stronger in adenocarcinoma with a brain metastasis (67%) than in those without (28%) (31) . A recent comprehensive analysis of DNA, RNA, and proteins identified PI3K/mTOR-Rictor signaling pathway as a potentially druggable prognostic modulator in resected squamous cell lung cancer (32).
Brain tumors
Rictor protein was overexpressed in a panel of glioma cell lines and in 86% of glioma patient samples compared with normal brain, and associated with cells proliferation in vitro and tumor formation in vivo (33) . Increased Rictor levels were also observed in pediatric low-grade gliomas, grade I and II astrocytomas, and grade IV [glioblastoma (GBM)] (34-36). In vitro and in vivo studies revealed a Rictor-EGFRvIII synergism that leads to the formation of aggressive gliomas in association to higher mTORC2 activity (36, 37) . Combined silencing of RICTOR and EGFR reduced cell migration and increased the sensitivity of GBM cell lines to chemotherapy. In an in vivo setting, dual silencing of RICTOR and EGFR resulted in complete tumor regression (38) . PTEN negatively regulates the assembly and activity of the mTORC2 complex by facilitating the phosphorylation of Rictor at Thr1135 rendering it unable to associate with the mTOR in GBM (39) . Natural (mahanine) and synthesized (CID613034 and JR-AB2-01) molecules have shown to induce anti-GBM and anti-lung-cancer effects with a Rictor-dependent manner in in vitro and in vivo experiments (39) (40) (41) . microRNAs have a critical role in epigenetic regulation of RICTOR expression (Figure 2 ). The downregulation of the miR-153 was correlated with elevated RICTOR mRNA and protein levels along with Akt S473 phosphorylation both in a set of human glioma samples and cell lines. In vitro and in vivo overexpression of miR-153 inhibited glioma cell proliferation, enhanced apoptosis and led to a dramatic decrease of tumor growth in mice (42) .
Gastrointestinal tumors
Rictor protein overexpression was detected in 70.6% of esophageal squamous cell carcinoma and 74.0% of gastric cancers and associated with shorter OS and higher tumor stage (43, 44) . Retrospective studies performed in colorectal cancer (CRC) showed higher RICTOR mRNA and protein expression levels compared with adjacent tissues, with an undefined impact on patients' prognosis (45, 46 
Genitourinary tumors
Endometrial carcinoma samples revealed higher RICTOR mRNA and protein levels than the normal endometrium samples (52, 53) . Rictor-positive immunostaining was an independent prognostic factor for OS and its combination with other clinicopathological risk factors produced an even more efficient prognostic model (52) . DNA hypermethylation around the CpG islands of miR-152 and the downregulation of its expression were present in 100% of both endometrial carcinoma cell lines and primary tumor samples. The tumor suppressor role of miR-152 was further supported by the identification of Rictor as one of its targets (53) . Data from a recent study showed that in human prostate cancer (PCa) cells, miR-218 targets directly the 3′-UTR of RICTOR and impairs the tumor proliferation and angiogenesis both in vitro and in vivo (54 
Breast cancer
Rictor protein levels were significantly upregulated in more aggressive breast cancers (BC) of grade II/III compared with I/ II, suggesting the relevance of Rictor in BC progression (58) . Moreover, Rictor overexpression was reported in Her-2 amplified BC cells. Exposure of Her-2 amplified cells to a dual mTORC1/2 inhibition along with lapatinib (a dual Her-2 and EGFR tyrosine kinase inhibitor), completely abolished the phosphorylation of Akt S473 (58) . A novel nanomedicine-based delivery strategy with therapeutical perspectives has been tested in Her-2 amplified and triple-negative breast cancer models. RICTOR siRNA-loaded nanoparticles decreased cancer cell growth when administered in vivo either via intravenous or intratumoral injection. Importantly, in the presence of lapatinib, this combination revealed a higher activity than lapatinib alone, thus proposing a potentially functional, stable, and tolerable therapeutical approach (59) . Rictor was also found to be highly expressed in 64.0% of ductal BC tissues and in 92.0% of metastatic lymph nodes (60) . The involvement of Rictor in BC metastatization competence was assessed both in vitro by measuring woundhealing following genetic silencing and in vivo by implantation of RICTOR-deficient cells. RICTOR-deficient cells were unable to close the wound, whereas tumor growth and BC cells dissemination to the lungs were significantly reduced compared with RICTOR-proficient cells (60) . The co-localization of Rictor and PKCζ in the leading edge of migrating cells suggested the mTORindependent Rictor-PKCζ interaction and its role in the BC cells motility (60) ( Table 3) .
Head and neck tumors
Oral squamous cell carcinoma exhibited Rictor immunostaining in 68% of cases (61) . miR-218 was reported as silenced by DNA hypermethylation in oral squamous cell carcinoma and a deeper investigation revealed Rictor as a target of this microRNA (62) . Epigenetic regulation of RICTOR in multidrug-resistant tongue cancer has been associated with miR-491-3p that directly targets RICTOR mRNA and blocks mTORC2 function. Tongue cancer patients with low levels of this microRNA and high expression of Rictor experienced a significantly worse OS than patients with high microRNA levels but low levels of Rictor (63).
Sarcomas
Co-amplification of RICTOR and TRIO (both located in the 5p arm) was observed in myxofibrosarcoma samples. High mRNA levels of both genes were found in 42% of samples and correlated with shorter disease-specific survival. Upon RICTOR silencing in Rictor-overexpressing myxofibrosarcoma cell lines, growth inhibition, and apoptosis were observed along with decreased phosphorylation level of Akt S473 and Akt T308 (64) . Rictor expression was detected approximately in 20% of sarcoma samples, mainly leiomyosarcoma (65) . Human vascular tumors are characterized by the increased activity of PI3K/Akt signaling (66) . An in vivo study in mouse hemangioendothelioma xenograft models revealed that RICTOR knockdown restricted vascular tumor growth. This finding might have clinical implication for human vascular malignancies that expand from benign hemangioma in children to malignant angiosarcoma in adults (67) .
Hematological tumors
Genetic depletion of RICTOR in murine models of acute myeloid leukemia caused hyperactivation of mTORC1 complex resulting in the disruption of the quiescence of the leukemic stem cells, pushing larger populations of them to enter the cell cycle (68) . RICTOR deletion in a mouse model of T cell-Acute Lymphoblastic Leukemia (T-ALL) resulted in less leukemic cells in liver, kidney, and lung and prolonged the life of T-ALL mice (69) . The upstream of mTORC2 (UT2), which interacts specifically with the mTORC2-Rictor, has been identified in hematopoietic progenitor cells as an intrinsic inhibitor of the complex kinase activity. Of note, its overexpression in T-ALL mice prolonged their survival (70). 
Other
In hepatocellular carcinoma, RICTOR mRNA has been shown to be the target of the miR-185, which is able to inhibit proliferation of HepG2 cells (71) . Analysis of human hepatocellular carcinoma revealed RICTOR copy number gains in 25% of cases that, alone or combined with phosphorylated ribosomal protein S6 (p-RPS6), were associated with disease recurrence (72) . Post-resection hepatocellular carcinoma patients with high Rictor/Raptor ratio and elevated levels of RICTOR mRNA experienced early recurrence and reduced disease-free survival (73) . Knockdown experiments against RICTOR or pharmacological blockade with AZD2014 abrogated pancreatic ductal adenocarcinoma development in in vivo models, extending significantly their OS (74) . Analysis of resected pancreatic ductal adenocarcinoma revealed that cases with high Rictor expression had a poorer OS than those with medium or low levels (75) . Epidermisspecific deletion of RICTOR prior to a protocol of chemicalinduced carcinogenesis resulted in the reduction of skin tumor incidence (38%) compared with control groups (100%) (76) . In addition, a delay in tumor onset, lower number of papillomas and tumor burden were also observed in RICTOR knockout mice.
Repeating the same experiment in mice with preestablished skin tumors revealed that RICTOR deletion led to their regression (76) . Patients with malignant pheochromocytoma, a rare tumor of neuroendocrine origin, exhibited strong Rictor positivity in 80.6% and moderate levels in 16.1% of pheochromocytoma samples. Genetic silencing of RICTOR in pheochromocytoma cells suppressed their proliferation and abrogated cell motility and invasion capability (77) .
mTOR-independent Rictor-containing complexes
Several preclinical data suggested that Rictor might be part of other protein complexes that do not include mTOR itself or other mTORC2 components. These complexes have been shown to exhibit either oncogenic or tumor suppressor properties, thus expanding the range of biological activities attributed to Rictor (Table 3 ). In particular, Rictor has been proposed as a scaffold protein for integrin-linked kinase (ILK), a β1-integrin interacting protein with kinase activity. The mTOR-independent ILK/Rictor complex was detected in several cancer cell lines and appeared to be mandatory for transforming growth factor beta-1-mediated epithelial-mesenchymal transition. The stability of ILK/Rictor complex and its ability to mediate phosphorylation of Akt S473 were not disrupted even after mTOR depletion in MDA-MB-231 cells. On the other hand, knockdown of either RICTOR or ILK decreased the levels of Akt S473 phosphorylation leading to significant increase in cell death (78, 79) . Another Rictor-containing complex is composed of tetraspanin 8 and integrin a3, which is present in human glioma tissues and cell lines and is required for the assembly and function of mTORC2 complex in GBM cells (80) . On the other hand, in CRC cells the assembly of Rictor with F-box and WD repeat domain containing 7 defines an E3 ligase complex that exerts an anti-oncogenic activity by promoting degradation of two well-defined oncogenes, c-Myc and cyclin E (81) . Similarly, Culin-1 interacts exclusively with Rictor, but not mTOR or other mTORC2 subunits, and defines a complex with E3 ubiquitination ligase activity that targets and degrades the downstream mTORC2 effector serum/glucocorticoid-induced kinase 1 (82) . Programmed cell death protein 4 is a tumor suppressor protein that establishes a complex with Rictor at the expense of mTORC2 formation in renal cancer, counteracting the metastatic behavior of the cells (83) . Furthermore, myosin IC was identified as a Rictor partner in adipocytes following immunoprecipitation experiments, which evidenced the absence of mTOR in this complex (84) .
Current status of targeting the PI3K/ mTOR/Akt pathway in clinic and future perspectives PI3K/mTOR pathway has been globally recognized as one of the most frequently dysregulated oncogenic signaling routes. Although numerous molecular inhibitors of PI3K/mTOR have been tested so far, only few have managed to be introduced in the clinical use to date. Although the safety profile of the majority of the available inhibitors does not represent the main concern, their clinical activity as monotherapy is usually limited. This suggests that rational combinatorial approaches should be designed (85) . The advent of reliable molecular biomarkers, which would accurately predict the PI3K/mTOR inhibitors sensitivity, is eagerly awaited. Early and limited clinical data have suggested that PI3K/mTOR/Akt inhibition has an increased efficacy in patients with PIK3CA mutations and AKT E17K mutations. However, other relevant studies presented contradictory findings, which calls for additional clinical trials in order to clarify the value of these molecular alterations as predictive biomarkers for PI3K/mTOR/Akt inhibitors (85). As we explored above, preclinical and clinical data suggested that RICTOR amplification, promoting mTORC2 signaling axis hyperactivation, might serve as a predictive biomarker for PI3K/mTOR/Akt inhibition. This notion is under evaluation in three ongoing single-arm phase II clinical trials with the dual mTORC1/2 inhibitor AZD2014 in SCLC (NCT03106155), solid tumor (NCT03166904) and stomach cancer (NCT03061708). In those trials, Rictor status is being assessed as amplification through sequencing and/or as protein overexpression via immunohistochemistry (IHC). For instance, in a single arm, multicenter phase II clinical trial, presently recruiting, 28 relapsed SCLC patients receive vistusertib (AZD2014) 50 mg BID per os every 12 hours as second or third line therapy. The aforementioned clinical trials applied NGS and Nanostring for copy number variation detection and IHC for assessment of Rictor protein levels. The IHC assay has been extensively applied in tumor samples for estimating Rictor expression levels, and NGS technology is frequently used for RICTOR copy number variation ( Table 2 ). The integration of a well-established diagnostic technique as IHC with an innovative high-throughput sequencing technology as NGS, might compose a comprehensive analyzing platform for determining RICTOR genetic and protein profile for recruiting in future clinical trials, borrowing the example of other tumors such as advanced gastric cancer (86) .
Conclusions
Given the fact that mTOR axis is involved in fundamental cellular events, the inhibition of mTOR pathway harbors high risk of severe toxicity. Moreover, to date, clinical trials evaluating different PI3K/mTOR inhibitors in unselected patients with different malignancies did not provide convincing evidence of activity. Therefore, the study of mTOR complexes as distinct signaling entities and the elucidation of the crosstalk mechanisms between them and other signaling pathways are considered of high priority. Collectively, this knowledge might lead to the design of more accurate therapeutic interventions, such as targeted inhibitors in a single or a combinatorial scheme, overcoming drug resistance, and mitigating side effects.
Is Rictor a relevant player in carcinogenesis?
The novel insights that are constantly coming into the spotlight have strengthened the incriminating role of Rictor in cancer onset and progression. RICTOR copy number gain and protein overexpression in cancers might be associated with higher mTORC2 activity, which has been repeatedly demonstrated to promote cell survival and migration in in vitro and in vivo cancer models. Based on these premises, Rictor might represent both a promising druggable target and a biomarker indicative of mTORC2 activation. Furthermore, although some prognostic differences according to tumor type and technique of analysis emerged, the majority of the available clinical reports suggest that Rictor overexpression, measurable as strong tissue immunostaining and RICTOR amplification by NGS or FISH, are associated with dismal prognosis in several cancer types. A more extensive correlation between mTORC2-RICTOR aberrations and survival outcomes from large datasets (i.e. The Cancer Genome Atlas) is mandatory in order to define the specific impact of this alteration according to the tumor type and disease characteristics. Rictor possesses a privileged position in the mTOR network by determining the formation of the mTORC2 complex, as well as it appears to be involved in many mTOR-independent complexes. As it has been reported in GBM, PTEN negatively regulated the mTORC2 formation by phosphorylating Rictor in T1135, whereas PTEN-deficient PCa cells required mTORC2-Rictor presence for inducing tumor formation in nude mice (39, 55) . Furthermore, PTEN partial or complete loss together with loss of protein expression has been reported in well-differentiated leiomyosarcoma. Interestingly, Rictor has been reported overexpressed in the well-differentiated leiomyosarcoma (65) . Collectively, there are indications for a potential inverse relationship between PTEN and mTORC2-Rictor, although additional confirmatory studies should be performed.
Potential benefits of selective mTORC2-Rictor inhibition in cancer
Although the development of mTOR pathway inhibitors is always in the center of the scientific community's attention, currently, the establishment of a truly mTORC2-Rictor-specific inhibitor has proved more challenging than it was initially envisaged. The available mTOR inhibitors lack specificity as they target both the mTOR complexes, thereby releasing mTORC1-mediated negative regulation of PI3K and mTORC2 activation. The lack of this complex feedback loop in the presence of dual mTORC1/2 targeting agents evidently limits potential clinical benefit obtainable instead from mTORC2-specific inhibition. A large amount of studies has repeatedly recognized Rictor as a fundamental partner of mTORC2. Therefore, the generation of a Rictor-specific inhibitor could result exclusively in the inhibition of mTORC2 assembly and activation. Considering the limited efficacy of PI3K/mTOR/ Akt agent as monotherapy, the design of rational treatment combinations is strongly required. Different studies have suggested the implication of mTORC2-Rictor in modulating chemotherapy and targeted therapy activity, providing the rationale for a customized combinatorial strategy to be established according to the specific tumor type. In this regard, genetic silencing of RICTOR restored the sensitivity of ovarian cancer to cisplatin and promoted trastuzumab activity in Her-2 amplified BC models. Moreover, co-silencing of mTORC2/RICTOR and EGFR increased the sensitivity to commonly used anti-GBM chemotherapy in cell lines and eradicated the tumor in in vivo models, highlighting the urgent need for the development of a selective mTORC2-Rictor inhibitor for single or combinatorial treatment (38, 57, 59) .
Integrating clinical and translational research towards PI3K/mTOR signaling pathway inhibition
It is noteworthy that a clinically relevant proportion of lung cancer cases presented RICTOR amplification as the only potentially actionable alteration. Intriguingly, a lung adenocarcinoma patient with a focal RICTOR amplification was treated with dual mTORC1/2 inhibitors and his disease remained remarkably stable. Collectively, these findings reinforce the rationale for clinical studies designed for patients with a specific molecular background and, specifically, exploring the efficacy of mTORC1/2 inhibitors in cancer patients with Rictor-related alterations. In conclusion, the dysregulation of mTORC2 components and downstream effectors is increasingly emerging as a common finding across tumor types. However, the oncogenic properties of mTORC2 have been only recently identified, implying the necessity of a deeper understanding of its tumor-promoting mechanisms as well as its connection with other interacting routes involved in the PI3K/mTOR signaling pathway. Unfortunately, the current status of PI3K/mTOR pathway inhibitors does not yet fulfill the patients' treatment needs. However, stratification of patients according to specific genetic alteration (PIK3CA mutations, RICTOR amplification) might reveal the therapeutic potential of the existing and upcoming molecular inhibitors. 
